A non-randomized, prospective, multicenter, observational, post-authorization study to assess the efficacy of Pelgraz® (pegfilgrastim) in the primary prevention of febrile neutropenia in patients receiving high risk myelosuppressive chemotherapy (ACCPEG1)

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Other
• Data sources (types), other:
  Prospective patient-based data collection

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No